Compass Therapeutics, Inc. (CMPX)
2.52
+0.12
(+5.00%)
USD |
NASDAQ |
Aug 25, 16:00
2.50
-0.02
(-0.79%)
After-Hours: 19:59
Compass Therapeutics Enterprise Value : 261.97M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 261.97M |
| August 21, 2026 | 261.97M |
| August 20, 2026 | 254.76M |
| August 19, 2026 | 276.37M |
| August 18, 2026 | 260.16M |
| August 17, 2026 | 245.76M |
| August 14, 2026 | 234.95M |
| August 13, 2026 | 236.75M |
| August 12, 2026 | 256.56M |
| August 11, 2026 | 225.95M |
| August 10, 2026 | 229.55M |
| August 07, 2026 | 216.94M |
| August 06, 2026 | 188.13M |
| August 05, 2026 | 170.12M |
| August 04, 2026 | 186.33M |
| August 03, 2026 | 169.22M |
| July 31, 2026 | 173.72M |
| July 30, 2026 | 179.12M |
| July 29, 2026 | 179.12M |
| July 28, 2026 | 197.13M |
| July 27, 2026 | 204.34M |
| July 24, 2026 | 202.54M |
| July 23, 2026 | 211.54M |
| July 22, 2026 | 197.13M |
| July 21, 2026 | 207.94M |
| Date | Value |
|---|---|
| July 20, 2026 | 193.53M |
| July 17, 2026 | 198.93M |
| July 16, 2026 | 207.94M |
| July 15, 2026 | 215.14M |
| July 14, 2026 | 224.15M |
| July 13, 2026 | 236.75M |
| July 10, 2026 | 249.36M |
| July 09, 2026 | 245.76M |
| July 08, 2026 | 251.16M |
| July 07, 2026 | 247.56M |
| July 06, 2026 | 242.16M |
| July 02, 2026 | 238.55M |
| July 01, 2026 | 222.35M |
| June 30, 2026 | 224.15M |
| June 29, 2026 | 204.09M |
| June 26, 2026 | 189.69M |
| June 25, 2026 | 187.89M |
| June 24, 2026 | 178.88M |
| June 23, 2026 | 186.09M |
| June 22, 2026 | 193.29M |
| June 18, 2026 | 178.88M |
| June 17, 2026 | 184.28M |
| June 16, 2026 | 169.88M |
| June 15, 2026 | 182.48M |
| June 12, 2026 | 180.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Upstream Bio, Inc. | 101.68M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.15M |
| Total Expenses (Quarterly) | 25.15M |
| EPS Diluted (Quarterly) | -0.1347 |
| Earnings Yield | -15.97% |
| Normalized Earnings Yield | -15.97 |